Rapidly bring the
candidates to commercialization
Technology PlatformsVHH antibody (Nb) is a single-domain antibody containing only VHH domain. Because the VHH crystal has a diameter of 2.5 nm, a length of 4 nm and a molecular weight of only about 15 kDa, which is one tenth of the traditional antibody, it is called VHH antibody®(Ablynx N.V.）. In 1989, Belgian scientists first discovered NANOBODIES®(Ablynx N.V.） in camel blood. With the multiple advantages of small size and easy design, NANOBODIES® (Ablynx N.V.） are gradually being regarded as a substitute for traditional monoclonal antibodies for clinical treatment and other applications. They are not only alternatives, but their unique functional characteristics have expanded the application of biotherapy and changed the mode of disease treatment, with huge market potential.
（VHH：variable domain of the heavy chain of heavy-chain antibody）
Technology Platforms
Biologcial drug inhalation platform For asthma, COPD,COVID-19 and other respiratory deseases;
Drug directly dilivered to the pathological site with high drug usage rate and low systemic toxicity;
Compatable with more portable nebulizer.
Reserve 300 camel immune libraries;
Involving 500 molecular targets;
Specific antibody molecules were obtained efficiently within 3 months.
The first Pichia pastoris based platform for VHH antibody development in China;
Leading technology in Pichia pastoris fermentation,with the yield more than 20g/L;
500L scale pilot production capacity.
Low molecular weight; Simple structure; There is no mismatch;
High expression level and purification yield;
Stable mass production.
Long-acting strategy based on appropriate HSA targeting VHH antibody;
Meet different clinical half-life requirements;
Wide application scenarios.
